Navigation Links
Business of drug development on verge of great change
Date:4/1/2008

Significant changes to drug discovery and the pharmaceutical industry currently underway will increase in the next five to 10 years, according to a top researcher at the National Institutes of Health (NIH) who is helping transform the business of drug research and development.

According to Christopher Austin, M.D., director of the NIH Chemical Genomics Center (NCGC), both industry and academia welcome more cooperation in drug discovery to secure more efficient results for less financial burden than if they operate independently. The increased participation of the public sector in therapeutics development is a trend that will be good for industry, academia, scientific discovery and the public at large, says Dr. Austin.

These collaborative efforts have been facilitated by researchers moving from industry to academia to help close the gap that exists between basic early stage research and the identification of viable drug candidates for a range of diseases, particularly those that are less prevalent or for which the targets are less well validated. The hope is that better drugs to treat more diseases will be developed faster and less expensively than ever before.

Not only is Dr. Austin a scientist who wants his work to improve the lives of people affected by disease, he also is a former pharmaceutical industry researcher who understands the business of drug development, having previously worked at Merck & Co. for a number of years. Hes observed that industry scientists are constrained in the scope of targets and diseases they study by commercial regulations imperatives which do not exist in the public sector. The work we do at the NCGC is complementary to what industry does we work on the 90% of new targets and diseases that industry doesnt, and we make our data publicly available so all researchers, public and private, can use it to advance drug discovery.

Marcie Glicksman, Ph.D., senior director of lead discovery, laboratory of drug discovery at the Harvard NeuroDiscovery Center and one of several co-presenters at the SBS meeting, also came from industry and has high hopes for the increased collaboration between Big Pharma and academia in drug discovery. At Harvard, our mission is to develop new therapeutics for diseases with no disease modifying treatments such as Parkinsons and Alzheimers, or orphan diseases such as Huntingtons and Amyotrophic Lateral Sclerosis (Lou Gehrigs), she states. There are smaller numbers of patients affected by orphan diseases -- treatments for them are not considered billion dollar drugs, so they are much harder to develop in industry.

Like Dr. Austin, Dr. Glicksman says its simply too expensive for industry to conduct this early stage research, and that is why the academic centers are so vital to the future of drug discovery for diseases that industry cant address on its own.

Dr. Austin and Dr. Glicksman will speak at a session on this topic at the 14th Annual Conference & Exhibition of the Society for Biomolecular Sciences (SBS) April 6-10 at Americas Center in St. Louis.


'/>"/>

Contact: Jennifer Bender
jbender@environics-usa.com
203-325-8772 x18
Society for Biomolecular Sciences
Source:Eurekalert

Related medicine news :

1. Underwriters Laboratories Management System Registration Business to Merge With Germanys DQS
2. Integrated Benefits Institute and National Business Coalition on Health to Host First Annual Health and Productivity Forum
3. Medical Marketing Veteran Signs on as Director of Strategy and New Business Development at Active Imagination
4. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update
5. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
6. Barr Announces Reorganization of Senior Management, Business Functions
7. Small Business Health Care Survey Points to Need for Reform
8. Guardian Expands Dental Benefit Options Helps Small Business Owners Lower Insurance Cost
9. Caring.com Adds Vice President of Business Development
10. Cantel Medical Corp. and National Safety Council Launch Joint Initiative to Prepare Businesses and Individuals for Flu Pandemic
11. Natural Nutrition Renames Former Business Lending Subsidiary i-Nutrition, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology: